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Abstract
Background Rituximab (RTX) has recently been introduced
as a second-line therapy for nephrotic syndrome in children.
Studies show that RTX given during the nephrotic state may
be less effective than treatment during a non-nephrotic state,
possibly due to loss of RTX in the urine.
Case-Diagnosis/Treatment We describe a 10-year-old boy
with steroid-resistant nephrotic syndrome (SRNS) treated
with RTX during a phase of active non-selective proteinuria.
The serum half-life of RTX in this patient was less than 1 day
compared to 20 days in patients without protein losses. Uri-
nary clearance was at least 25 %, compared to approximately
0 % in control patients. However, RTX loss in the urine, as
well as in pleural effusion and ascites, only partly explains the
rapid drop in the serum RTX concentration of this patient.
Conclusions Serum half-life of RTX can be extremely short,
partly due to excessive urinary losses in therapy-resistant
nephrotic syndrome with non-selective proteinuria, as seen
in our patient. These findings may help to explain the poor
results of RTX treatment in patients with active proteinuria.
Background
Over the last few years rituximab (RTX), a humanized mono-
clonal antibody against CD20+ B cells, has been introduced as a
second-line therapy for nephrotic syndrome in children non-
responsive to standard therapies. B cells produce (auto)-antibod-
ies, generate pro-inflammatory cytokines and function as mod-
ulators of inflammation, and are efficient antigen-presenting
cells [1]. Although nephrotic syndrome is thought to be primar-
ily a Tcell-mediated disease, anti-B cell therapy probably has an
immunomodulatory effect on the disease course [2, 3].
Several studies have shown that RTX given during the ne-
phrotic state may be less effective than treatment during a non-
nephrotic state (i.e., in remission) [2, 4, 5], possibly due to the
loss of RTX in the urine [2, 5–7]. However, to date, there has
been no pharmacokinetics-based evidence for this hypothesis.
Here we present a patient with steroid-resistant nephrotic
syndrome (SRNS) treated with RTX during a phase of active
proteinuria. The clearance of RTX was extremely fast, partly
explainable by excessive urinary losses.
Case report
A 10-year-old Afro-American boy (36 kg), diagnosed with
idiopathic nephrotic syndrome for 3 years, was treated initially
with prednisolone (1.5 mg/kg/day) and then for a shorter time
with mycophenolate mofetil (MMF) partly in combination
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with cyclosporine. His caretaker refused to continue the ad-
vised cyclosporine + MMF treatment or to switch to tacroli-
mus and only gave him high-dose prednisolone for more than
1 year. In this year he developed steroid resistance. A kidney
biopsy—taken shortly before treatment with RTX—showed
minimal change nephropathy.
On admission the patient was Cushingoid and had protein-
uria with significant peripheral edema, pleural and pericardial
effusion, and ascites. Following drainage of the pleural, peri-
cardial, and peritoneal fluid he showed clinical improvement.
Laboratory results demonstrated elevated serum creatinine
[91 μmol/L; estimated glomerular filtration rate 60 mL/min/
1.73 m2; normal range 80–120 mL/min/1.73 m2 (Schwarz
formula)], elevated blood urea nitrogen (8.2 mmol/L; normal
range 1.8–6.4 mmol/L), and severe hypoalbuminemia (≤15 g/
L; normal range 35–55 g/L). Serum immunoglobulin G (IgG)
was extremely low (0.25 g/L; normal range 5.2–15.6 g/L),
probably due to non-selective proteinuria. Urinalysis showed
severe proteinuria (21.5 g/L; >2220 mg albumin/mmol creat-
inine), with a low selectivity index of 0.33 [(urine IgG/serum
IgG) × (serum albumin/urine albumin)]. The clinical decision
to treat the patient with RTX was made in order to achieve
quick clinical improvement.
RTX was started at a dose of 375 mg/m2, and serum con-
centrations of RTX and B lymphocyte counts were measured.
The concentration of RTX in serum samples was determined
using a direct enzyme-linked immunosorbent assay [see Elec-
tronic Supplementary Material (ESM)]. RTX concentrations
fell very quickly (Fig. 1a), and at 14 days after the initiation of
RTX therapy, complete CD20+ B cell depletion was docu-
mented (<10 CD20+ B cells/μL) (Fig. 1b); however, as quick-
ly as 1 week later CD20+ B lymphocytes reappeared. The
next three RTX doses were given at shorter intervals, with a
target serum RTX concentration of >10 μg/L (20, 24 and
31 days after the first dose, respectively). This therapeutic
strategy achieved CD20+ B lymphocyte depletion from day
19 to day 39. A few circulating CD19+ B lymphocytes were
still present at day 39, but after day 39 B lymphocytes were
not tested anymore. The elimination serum half-life of RTX in
our patient was <1 day, compared to 20 days in a group of
patients receiving RTX post-stem cell transplantation. These
latter patients had no urinary protein loss, normal kidney func-
tion, and no ascites (C.M. Jol–van der Zijde; unpublished
observations). High concentrations of RTX were found in
our patient’s urine and pleural fluid (Fig. 1a).
The population pharmacokinetics of RTXwas simulated in
a two-compartment structure [8, 9], with additional simula-
tions for urinary and pleural fluid loss, using the software
package R 2.12 (see ESM Table 2). Urinary clearance, as
derived from the measurements of RTX concentrations in
the urine and urine production, was at least 25 % of the total
clearance, whereas in stem cell transplantation patients with-
out proteinuria, urinary clearance was nil. Pleural clearance, as
derived from RTX concentrations in pleural fluid and the
drained amount of pleural fluid, was around 2 % of the total
clearance (data not shown). However, these losses explained
Fig. 1 Level of rituximab (RTX)
and B cells after initiation of RTX
therapy in nephrotic patient. a
RTX levels in serum (black line),
urine (gray line), and pleural fluid
(diamonds) over time (days) in
relation to four RTX infusions.
Gray area in left upper part
indicates RTX levels of patients
receiving RTX post-stem cell
transplantation without urinary
protein loss. b Simultaneous
measurements of CD19+ and
CD20+ B cells. Gray line Our
definition of CD20+ B cell
depletion of <10 CD20+ B cells/
μL
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only part of the rapid drop in serum RTX concentration. An-
tibodies against RTX could not be detected [10].
Because of ongoing proteinuria and ascites, pleural and
pericardial effusions after the four doses of RTX, and severe
hypertension, an angiotensin-converting enzyme-inhibitor
(enalapril), diuretics, and tacrolimus were added to the thera-
peutic regimen. Four months after the first dose of RTX, pred-
nisolone was tapered and could be stopped. Six months after
RTX treatment, the patient still had proteinuria (1000 mg
albumin/mmol creatinine), but he was in a stable situation,
without edema and with normal blood pressure, under treat-
ment with tacrolimus, ramipril, and hydrochlorothiazide.
Discussion
To our knowledge, this is the first report of the pharma-
cokinetic profile of RTX in a patient in a nephrotic state
demonstrating excessive urinary loss of RTX. Previous
publications have shown that RTX treatment may be less
effective for SRNS than for steroid-dependent (SDNS) or
frequently-relapsing nephrotic syndrome [2, 4, 5, 11, 12].
In a large retrospective multicenter study of 70 nephrotic
patients [4], 41 % (11/27 with SRNS) had minimal
change nephrotic syndrome (MCNS), similar to our pa-
tient, but no information on the amount of proteinuria
was reported by the authors. Of the 27 SRNS patients,
12 (44 %) had a good initial response to RTX, of whom
four (33 %) had MCNS and six (50 %) had focal seg-
mental glomeruloscerlosis. Of the 28 patients with
SDNS, 23 (82 %) had a good initial response to RTX
[4]. In a more recent randomized controlled trial involv-
ing 31 patients with SRNS [11], half of the patients were
treated with RTX (375 mg/m2; two injections, with a 2-
week interval between injections). All patients were con-
currently treated with prednisolone or cyclosporine. After
3 months of follow-up, responses were similar in both
groups. None of the early SRNS patients had a good
response. Among six SRNS patients who developed
prednisolone resistance months or years after disease on-
set, those in the RTX group showed some response, es-
pecially those who had responded to standard drugs ear-
lier [11]. The poor results in the SRNS group may have
been due to the loss of RTX in the urine [2, 5–7].
Few studies have focused on the pharmacokinetics of
RTX in patients with nephrotic syndrome [7, 11, 13]. The
mean serum half-life of RTX in patients with SDNS is
reported to be 14.6±5.2 days (no information was provid-
ed by these authors on proteinuria) [13], which is only
slightly shorter than the 20 days in patients who received
RTX for other indications (i.e., reactivation of Epstein–
Barr virus after allogeneic stem cell transplantation; C.M.
Jol–van der Zijde, unpublished observations). In contrast,
the serum half-life of RTX in our patient was <1 day.
Fervenza et al. [7] measured plasma RTX concentrations
in 15 patients with severe proteinuria and found that 14
days after RTX infusion the plasma concentration was 17±
11 μg/mL. In our patient, the plasma RTX level was already
<0.1 μg/mL after 7 days. One possible explanation for these
differences in serum half-life and plasma RTX concentra-
tions is that our patient had severe non-selective protein-
uria; consequently, RTX, with an approximate molecular
weight of 145 kDa, was lost in the urine, causing insuffi-
cient RTX exposure to deplete all circulating CD20+ B
cells. While the duration of B cell depletion in patients
with refractory nephrotic syndrome was previously report-
ed to be approximately 3–5 months [14, 15], in our pa-
tient B cells reappeared within 20 days after the first dose
of RTX, probably due to the short serum half-life of RTX;
additional losses in the pleural effusion and ascites in our
patient contributed to the shortening of the serum RTX
half-life. Nevertheless, the pharmacokinetics studies in
our patient and the simulation studies only partly explain
the extremely short serum half-life of RTX. Other factors
which could be of importance in this respect are intra-
vascular dehydration, stimulation of the metabolism of
RTX by the liver due to hypo-albuminemia, and/or an
effect of Fcγ gamma receptor polymorphisms [16].
Our initial aim was to treat our patient with one dose
of RTX. When B cells reappeared shortly thereafter how-
ever, we decided to provide a full treatment with four
doses, measuring urinary RTX loss and serum RTX con-
centrations after each infusion. The timing of each follow-
ing dose of RTX was chosen to maintain the serum RTX
concentration at >10 μg/mL in order to achieve more
prolonged B cell depletion. Despite this strategy, stable
remission of the nephrotic syndrome was not immediately
achieved, and additional treatment modalities were neces-
sary. Although B cell depletion itself is thought to be an
important factor affecting the long-term effectiveness of
RTX treatment, Guigonis et al. [2] reported that complete
B cell depletion is necessary but not sufficient for RTX to
be effective in SDNS. The pharmacokinetics of RTX may
be affected by the nephrotic state, leading to only a partial
depletion of non-circulating B cells (CD20+) despite com-
plete depletion of circulating B cells (CD20+) [2, 5]. On
the other hand, Prytula et al. [4] reported that two children
without CD19+ B cell depletion showed good clinical
response to RTX. Additionally, it has been reported that
clinical remission can last longer than the depletion of B
cells in the peripheral blood [2], suggesting additional ef-
fects of anti-B cell therapy [1, 3].
In conclusion, the serum half-life of RTX can be ex-
tremely short in patients with therapy-resistant nephrotic
syndrome with non-selective proteinuria, partly because
of excessive urinary loss. However, there must be other,
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as yet unidentified factors that contribute to this extremely
short half-life of RTX.
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